Cargando…

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

BACKGROUND: With the unprecedented morbidity and mortality associated with the COVID-19 pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac (Sinovac Life Sciences, Beijing, China), an inactivated vaccine candidate against COVID-19, containing inactivated severe acute r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yanjun, Zeng, Gang, Pan, Hongxing, Li, Changgui, Hu, Yaling, Chu, Kai, Han, Weixiao, Chen, Zhen, Tang, Rong, Yin, Weidong, Chen, Xin, Hu, Yuansheng, Liu, Xiaoyong, Jiang, Congbing, Li, Jingxin, Yang, Minnan, Song, Yan, Wang, Xiangxi, Gao, Qiang, Zhu, Fengcai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832443/ https://www.ncbi.nlm.nih.gov/pubmed/33217362 http://dx.doi.org/10.1016/S1473-3099(20)30843-4

Ejemplares similares

Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China
por: Hu, Yuemei, et al.
Publicado: (2019)

CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
por: Jin, Lairun, et al.
Publicado: (2022)

Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial
por: Zhu, Dandan, et al.
Publicado: (2022)

Effects of maternal antibodies in infants on the immunogenicity and safety of inactivated polio vaccine in infants
por: Gao, Shuyu, et al.
Publicado: (2022)

Development of an inactivated vaccine candidate for SARS-CoV-2
por: Gao, Qiang, et al.
Publicado: (2020)

A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia
por: Fadlyana, Eddy, et al.
Publicado: (2021)

Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials
por: Zhu, Fengcai, et al.
Publicado: (2022)

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
por: Wu, Zhiwei, et al.
Publicado: (2021)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer
por: Li, Tong, et al.
Publicado: (2022)

The Quantification of Spike Proteins in the Inactivated SARS-CoV-2 Vaccines of the Prototype, Delta, and Omicron Variants by LC–MS
por: Xu, Kangwei, et al.
Publicado: (2023)

The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18–59 years: A phase I randomized, double-blinded, controlled trial
por: Pu, Jing, et al.
Publicado: (2021)

Safety and immunogenicity of a modified Omicron-adapted inactivated vaccine in healthy adults: a randomized, double-blind, active-controlled Phase III clinical trial
por: Hu, Jialei, et al.
Publicado: (2023)

Safety, Immunogenicity and Lot-to-Lot Consistency of Sabin-Strain Inactivated Poliovirus Vaccine in 2-Month-Old Infants: A Double-Blind, Randomized Phase III Trial
por: Zheng, Yan, et al.
Publicado: (2022)

Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial
por: Jin, Pengfei, et al.
Publicado: (2022)

Immunogenicity and Safety of One versus Two Doses of Quadrivalent Inactivated Influenza Vaccine (IIV4) in Vaccine-Unprimed Children and One Dose of IIV4 in Vaccine-Primed Children Aged 3–8 Years
por: Shi, Yunfeng, et al.
Publicado: (2023)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
por: Zeng, Gang, et al.
Publicado: (2022)

Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
por: Jin, Pengfei, et al.
Publicado: (2021)

Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: A randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China
por: Shenyu, Wang, et al.
Publicado: (2022)

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial
por: Chappell, Keith J, et al.
Publicado: (2021)

Effect of seasonal coronavirus immune imprinting on the immunogenicity of inactivated COVID-19 vaccination
por: Yin, Di, et al.
Publicado: (2023)

Serotype specific epitopes identified by neutralizing antibodies underpin immunogenic differences in Enterovirus B
por: Wang, Kang, et al.
Publicado: (2020)

Immunogenicity of inactivated rotavirus in rhesus monkey, and assessment of immunologic mechanisms
por: Zhou, Yan, et al.
Publicado: (2023)

Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis
por: Zhang, Xiaoyin, et al.
Publicado: (2023)

Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light
por: Gracheva, A. V., et al.
Publicado: (2022)

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial
por: Hui, Ai-Min, et al.
Publicado: (2022)

The architecture of the SARS-CoV-2 RNA genome inside virion
por: Cao, Changchang, et al.
Publicado: (2021)

Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer
por: Han, Yuling, et al.
Publicado: (2022)

Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials
por: Pan, Hong-Xing, et al.
Publicado: (2021)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
por: Xia, Shengli, et al.
Publicado: (2021)

Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals
por: Li, Juan, et al.
Publicado: (2021)

Immunogenicity of a new, inactivated canine adenovirus type 2 vaccine for dogs
por: Yang, Dong-Kun, et al.
Publicado: (2020)

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies
por: Kandeil, Ahmed, et al.
Publicado: (2021)

Evaluation of Immunogenicity of an Inactivated SARS-CoV-2 Vaccine Prototype in vitro
por: Hancharou, Andrei, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccines in healthy adults
por: Wu, Yufei, et al.
Publicado: (2023)

Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
por: Li, Rongcheng, et al.
Publicado: (2008)

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial
por: Han, Bihua, et al.
Publicado: (2021)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial
por: Guo, Wanshen, et al.
Publicado: (2021)

Comparative Analysis of the Immunogenicity and Protective Effects of Inactivated EV71 Vaccines in Mice
por: Mao, Qunying, et al.
Publicado: (2012)

Preclinical immunogenicity assessment of a cell-based inactivated whole-virion H5N1 influenza vaccine
por: Zhang, Zhegang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lcae9l6o67qdnuki18abva99it